AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18006187 — intervention group
Group type: COMPARATOR
Intervention: Verbalise only control group
Number of subjects: 134
Study 16206364 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient self-report checklist for adverse events
Number of subjects: 0
Study 16206364 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigator-reported adverse event instruments
Number of subjects: 0
Study 16206364 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheumatology Common Toxicity Criteria
Number of subjects: 0
Study 11823658 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tPA
Number of subjects: 61
Study 11823658 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 10051051 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoral (CsA‐ME)
Number of subjects: 0
Study 10051051 — intervention group
Group type: COMPARATOR
Intervention: Sandimmune (CsA‐SIM)
Number of subjects: 0
Study 7486086 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine 0.125% (A 125)
Number of subjects: 30
Study 7486086 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine 0.25% (A 25)
Number of subjects: 30
Study 7486086 — intervention group
Group type: COMPARATOR
Intervention: saline 0.9% (A 0)
Number of subjects: 30
Study 7486086 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine 0.25% (B 25)
Number of subjects: 30
Study 7486086 — intervention group
Group type: COMPARATOR
Intervention: placebo (B 0)
Number of subjects: 30
Study 1979376 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate splinting
Number of subjects: 79
Study 1979376 — intervention group
Group type: COMPARATOR
Intervention: Sonographic surveillance for 2 weeks
Number of subjects: 79
Study 7006615 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 0
Study 7006615 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 0
Study 31557344 — intervention group
Group type: EXPERIMENTAL
Intervention: Partner-reported alcohol consumption
Number of subjects: 247
Study 31557344 — intervention group
Group type: EXPERIMENTAL
Intervention: Partner-reported AUDIT score
Number of subjects: 247
Study 31557344 — intervention group
Group type: COMPARATOR
Intervention: Self-reported AUDIT score
Number of subjects: 247
Study 24535044 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-1 (uncertain, with intercessory prayer)
Number of subjects: 45
Study 24535044 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-2 (uncertain, no intercessory prayer)
Number of subjects: 45
Study 24535044 — intervention group
Group type: COMPARATOR
Intervention: Control group (informed, no intervention)
Number of subjects: 45
Study 26130344 — intervention group
Group type: EXPERIMENTAL
Intervention: TXA group (2 intravenous injections of 1 g TXA pre- and post-operatively)
Number of subjects: 60
Study 22576416 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro‐myostimulation (EMS)
Number of subjects: 20
Study 22269195 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouth rinse containing Ocimum gratissimum (Og)
Number of subjects: 30
Study 22269195 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouth rinse containing chlorhexidine digluconate (CLX)
Number of subjects: 30
Study 22269195 — intervention group
Group type: COMPARATOR
Intervention: Control group (mouth rinse with no antiseptic agents)
Number of subjects: 30
Study 19250558 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment (indapamide SR 1.5 mg +/‐ perindopril 2‐4 mg)
Number of subjects: 3763
Study 19250558 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 3763
Study 17697550 — intervention group
Group type: EXPERIMENTAL
Intervention: Homemade tropisetron hydrochloride
Number of subjects: 118
Study 17697550 — intervention group
Group type: COMPARATOR
Intervention: Navoban (positive control agent)
Number of subjects: 118
Study 17697550 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of Life (QOL)
Number of subjects: 118
Study 17697550 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events occurrence rate
Number of subjects: 118
Study 15662146 — intervention group
Group type: EXPERIMENTAL
Intervention: d-methylphenidate hydrochloride (d-MPH) 10 mg twice-a-day
Number of subjects: 89
Study 15662146 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 15662146 — intervention group
Group type: EXPERIMENTAL
Intervention: d-methylphenidate hydrochloride (d-MPH)
Number of subjects: 89
Study 11696143 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg x kg(‐1) 0.2% ropivacaine + S‐ketamine 0.5 mg x kg(‐1)
Number of subjects: 63
Study 11696143 — intervention group
Group type: COMPARATOR
Intervention: 2 mg x kg(‐1) 0.2% ropivacaine + clonidine 2 microg x kg(‐1)
Number of subjects: 63
Study 11696143 — intervention group
Group type: COMPARATOR
Intervention: 2 mg x kg(‐1) 0.2% ropivacaine
Number of subjects: 63
Study 11074735 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (conjugated equine estrogens alone or in combination with progestins)
Number of subjects: 701
Study 11074735 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 701
Study 8923552 — intervention group
Group type: EXPERIMENTAL
Intervention: One-line or two-line pitched-from-vertical stimulus
Number of subjects: 0
Study 8923552 — intervention group
Group type: COMPARATOR
Intervention: Oblique one-line or two-line stimulus from an erect plane
Number of subjects: 0
Study 8923552 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitched-from-vertical lines
Number of subjects: 0
Study 8923552 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulus sequencing or subject naivety
Number of subjects: 0
Study 1315445 — intervention group
Group type: EXPERIMENTAL
Intervention: + oxaprotiline
Number of subjects: 10
Study 1315445 — intervention group
Group type: COMPARATOR
Intervention: - oxaprotiline
Number of subjects: 10
Study 3932228 — intervention group
Group type: EXPERIMENTAL
Intervention: HB 420 (1.75 mg)
Number of subjects: 10
Study 3932228 — intervention group
Group type: COMPARATOR
Intervention: HB 419 (2.5 mg)
Number of subjects: 10
Study 3932228 — intervention group
Group type: COMPARATOR
Intervention: HB 420 and Semi‐Euglucon
Number of subjects: 10
Study 3932228 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 10
Study 30218695 — intervention group
Group type: EXPERIMENTAL
Intervention: GFF MDI (28.8 μg/10 μg)
Number of subjects: 100
Study 30218695 — intervention group
Group type: EXPERIMENTAL
Intervention: GFF MDI (14.4 μg/10 μg)
Number of subjects: 100
Study 30218695 — intervention group
Group type: EXPERIMENTAL
Intervention: GP MDI (28.8 μg)
Number of subjects: 100
Study 30218695 — intervention group
Group type: EXPERIMENTAL
Intervention: GP MDI (14.4 μg)
Number of subjects: 100
Study 26412294 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuum intervention
Number of subjects: 1189
Study 26412294 — intervention group
Group type: EXPERIMENTAL
Intervention: Biogenetic intervention
Number of subjects: 1189
Study 26412294 — intervention group
Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 1189
Study 24662344 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine treatment for 8 weeks
Number of subjects: 59
Study 24662344 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine treatment for 28 weeks
Number of subjects: 59
Study 24662344 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy people), N=31
Number of subjects: 59
Study 22168465 — intervention group
Group type: EXPERIMENTAL
Intervention: Boiled egg food challenge
Number of subjects: 68
Study 22168465 — intervention group
Group type: EXPERIMENTAL
Intervention: Raw egg food challenge
Number of subjects: 68
Study 22168465 — intervention group
Group type: EXPERIMENTAL
Intervention: Gal d 1 positivity
Number of subjects: 68
Study 22168465 — intervention group
Group type: COMPARATOR
Intervention: Skin tests and other IgE tests
Number of subjects: 68
Study 22168465 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple specific IgE detection by ISAC
Number of subjects: 68
Study 20100958 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab with taxane/carboplatin (T/C)
Number of subjects: 676
Study 20100958 — intervention group
Group type: COMPARATOR
Intervention: Taxane/carboplatin (T/C) without cetuximab
Number of subjects: 676
Study 17594216 — intervention group
Group type: EXPERIMENTAL
Intervention: PBLI-DMEDS module
Number of subjects: 0
Study 17594216 — intervention group
Group type: COMPARATOR
Intervention: Standard curriculum
Number of subjects: 0
Study 16151816 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin-TDS
Number of subjects: 485
Study 16151816 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 485
Study 12241543 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldosterone (12 pmol.min(‐1).kg(‐1) for 4 h)
Number of subjects: 16
Study 12241543 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (single 50 mg dose)
Number of subjects: 16
Study 12241543 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 10095333 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipronation taping technique
Number of subjects: 14
Study 10095333 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporary felt orthosis
Number of subjects: 14
Study 10095333 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 14
Study 7587422 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salmeterol, 50 micrograms twice a day for seven doses
Number of subjects: 10
Study 7587422 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 7587422 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (200 micrograms) after salmeterol period
Number of subjects: 10
Study 2262371 — intervention group
Group type: EXPERIMENTAL
Intervention: Two hyperthermia treatments
Number of subjects: 70
Study 2262371 — intervention group
Group type: COMPARATOR
Intervention: Six hyperthermia treatments
Number of subjects: 70
Study 31128522 — intervention group
Group type: EXPERIMENTAL
Intervention: Baduanjin
Number of subjects: 69
Study 31128522 — intervention group
Group type: COMPARATOR
Intervention: Brisk walking
Number of subjects: 69
Study 31128522 — intervention group
Group type: COMPARATOR
Intervention: Education control
Number of subjects: 69
Study 30391912 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (Dex) administration (1 µg/kg loading dose before anaesthesia induction and 0.5 µg/kg/h infusion during surgery)
Number of subjects: 190
Study 30391912 — intervention group
Group type: COMPARATOR
Intervention: Saline control (CON group)
Number of subjects: 190
Study 30391912 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (Dex) administration
Number of subjects: 190
Study 27206218 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertuzumab plus topotecan (1.25 mg/m days 1-5 every 3 weeks)
Number of subjects: 50
Study 27206218 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertuzumab plus paclitaxel (80 mg/m weekly)
Number of subjects: 50
Study 25211297 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe burn injury
Number of subjects: 97
Study 22882932 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive rehabilitation (transcutaneous electrical nerve stimulation, mid-frequency electrotherapy, Tuina therapy, and occupational therapy)
Number of subjects: 43
Study 22882932 — intervention group
Group type: COMPARATOR
Intervention: Home-based electrical nerve stimulation and occupational therapy (Control)
Number of subjects: 43
Study 22882932 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive rehabilitation
Number of subjects: 43
Study 19559446 — intervention group
Group type: EXPERIMENTAL
Intervention: Daytime nap (40 minutes)
Number of subjects: 63
Study 19559446 — intervention group
Group type: COMPARATOR
Intervention: Wake condition
Number of subjects: 63
Study 18622588 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-aided guidance for discectomy and corpectomy (Trial Group)
Number of subjects: 26
Study 18622588 — intervention group
Group type: COMPARATOR
Intervention: No computer navigation (Control Group)
Number of subjects: 26
Study 16459945 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual medical care plus compliance therapy (4-6 sessions, 60 minutes each)
Number of subjects: 40
Study 16459945 — intervention group
Group type: COMPARATOR
Intervention: Usual medical care (n = 20)
Number of subjects: 40
Study 12856387 — intervention group
Group type: EXPERIMENTAL
Intervention: E5564 (350 micrograms)
Number of subjects: 28
Study 12856387 — intervention group
Group type: EXPERIMENTAL
Intervention: E5564 (1000 micrograms)
Number of subjects: 28
Study 12856387 — intervention group
Group type: EXPERIMENTAL
Intervention: E5564 (2000 micrograms)
Number of subjects: 28
Study 12856387 — intervention group
Group type: EXPERIMENTAL
Intervention: E5564 (3500 micrograms)
Number of subjects: 28
Study 12856387 — intervention group
Group type: EXPERIMENTAL
Intervention: E5564 (all doses)
Number of subjects: 28
Study 12856387 — intervention group
Group type: EXPERIMENTAL
Intervention: E5564 (2000 and 3500 micrograms)
Number of subjects: 28
Study 12856387 — intervention group
Group type: EXPERIMENTAL
Intervention: E5564 (up to 3500 micrograms)
Number of subjects: 28
Study 12856387 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 10391557 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative radiation therapy (IORT) of 12-25 Gy
Number of subjects: 121
Study 10391557 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative radiation therapy (IORT) of 25 Gy
Number of subjects: 121
Study 10391557 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative radiation therapy (IORT) of 12-20 Gy
Number of subjects: 121
Study 10391557 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative radiation therapy (IORT)
Number of subjects: 121
Study 8897331 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 40
Study 8897331 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 40
Study 8897331 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 40
Study 1515884 — intervention group
Group type: EXPERIMENTAL
Intervention: 44 mg/kg of VP‐16 + 103 mg/kg CY followed by 12 Gy TBI (autologous marrow recipients)
Number of subjects: 37
Study 1515884 — intervention group
Group type: EXPERIMENTAL
Intervention: 36 mg/kg of VP‐16 + 67 mg/kg CY followed by 12 Gy TBI (allogeneic marrow recipients)
Number of subjects: 37
Study 1515884 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of etoposide and cyclophosphamide with TBI
Number of subjects: 37
Study 1515884 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose limiting toxicities
Number of subjects: 37
Study 6828969 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefamandole
Number of subjects: 100
Study 6828969 — intervention group
Group type: COMPARATOR
Intervention: Combination of cephalothin-tobramycin
Number of subjects: 100
Study 30318931 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic prompting method
Number of subjects: 16
Study 30318931 — intervention group
Group type: COMPARATOR
Intervention: User-controlled method
Number of subjects: 16
Study 29352304 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily text messages
Number of subjects: 638
Study 29352304 — intervention group
Group type: COMPARATOR
Intervention: Control group (no text messages)
Number of subjects: 638
Study 26434564 — intervention group
Group type: EXPERIMENTAL
Intervention: Renin-angiotensin system (RAS) intervention
Number of subjects: 0
Study 26434564 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25187903 — intervention group
Group type: EXPERIMENTAL
Intervention: Endosseous implants with straight emergence profile, ZirTi surface, 3.3 to 5 mm diameter, and 8.5 to 13 mm length
Number of subjects: 252
Study 21812893 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone/Metformin (Rosi/Met, 4/1000 mg)
Number of subjects: 207
Study 21812893 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207
Study 19683303 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 shocks per minute
Number of subjects: 163
Study 19683303 — intervention group
Group type: COMPARATOR
Intervention: 120 shocks per minute
Number of subjects: 163
Study 17998769 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilnidipine (10 mg)
Number of subjects: 23
Study 15277960 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating electrical stimulation of the extensor and flexor muscles of the hand (group A)
Number of subjects: 30
Study 15277960 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation of the extensors only (group B)
Number of subjects: 30
Study 11990406 — intervention group
Group type: EXPERIMENTAL
Intervention: Buried catheter technique (B group)
Number of subjects: 60
Study 11990406 — intervention group
Group type: COMPARATOR
Intervention: Standard catheter technique (NB group)
Number of subjects: 60
Study 11990406 — intervention group
Group type: COMPARATOR
Intervention: Standard catheter technique (NS group)
Number of subjects: 60
Study 9824883 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenic patients
Number of subjects: 46
Study 9824883 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 46
Study 7808829 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey-predominant formula (Similac Special Care, whey:casein ratio 60:40)
Number of subjects: 20
Study 7808829 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein-predominant formula (whey:casein ratio 18:82)
Number of subjects: 20
Study 7808829 — intervention group
Group type: COMPARATOR
Intervention: Both formulas (whey-predominant and casein-predominant)
Number of subjects: 20
Study 2744943 — intervention group
Group type: EXPERIMENTAL
Intervention: Limbus-based conjunctival flap
Number of subjects: 0
Study 2744943 — intervention group
Group type: COMPARATOR
Intervention: Fornix-based conjunctival flap
Number of subjects: 0
Study 4152716 — intervention group
Group type: EXPERIMENTAL
Intervention: Ordinary Noveril
Number of subjects: 20
Study 4152716 — intervention group
Group type: EXPERIMENTAL
Intervention: Time released Noveril
Number of subjects: 20
Study 31617830 — intervention group
Group type: EXPERIMENTAL
Intervention: Survivorship planning consultation (experimental arm)
Number of subjects: 199
Study 31617830 — intervention group
Group type: COMPARATOR
Intervention: Time-attention control - wellness rehabilitation intervention (control arm)
Number of subjects: 199
Study 29311072 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefiderocol 100 mg
Number of subjects: 70
Study 29311072 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefiderocol 250 mg
Number of subjects: 70
Study 29311072 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefiderocol 500 mg
Number of subjects: 70
Study 29311072 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefiderocol 1000 mg
Number of subjects: 70
Study 29311072 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefiderocol 2000 mg
Number of subjects: 70
Study 29311072 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefiderocol 1000 mg q8h
Number of subjects: 70
Study 29311072 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefiderocol 2000 mg q8h
Number of subjects: 70
Study 29311072 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 28845435 — intervention group
Group type: EXPERIMENTAL
Intervention: Sintered nanohydroxyapatite (NHA)
Number of subjects: 28
Study 28845435 — intervention group
Group type: COMPARATOR
Intervention: Anorganic bovine bone (ABB)
Number of subjects: 28
Study 28845435 — intervention group
Group type: EXPERIMENTAL
Intervention: NHA
Number of subjects: 28
Study 28845435 — intervention group
Group type: COMPARATOR
Intervention: ABB
Number of subjects: 28
Study 25393772 — intervention group
Group type: COMPARATOR
Intervention: Fresh red blood cell transfusions (<14 days)
Number of subjects: 43
Study 25393772 — intervention group
Group type: EXPERIMENTAL
Intervention: Older stored red blood cell transfusions (>21 days)
Number of subjects: 43
Study 23293218 — intervention group
Group type: EXPERIMENTAL
Intervention: IMSI (high-magnification intracytoplasmic morphologically selected sperm injection)
Number of subjects: 350
Study 23293218 — intervention group
Group type: COMPARATOR
Intervention: ICSI (conventional intracytoplasmic sperm injection)
Number of subjects: 350
Study 23293218 — intervention group
Group type: EXPERIMENTAL
Intervention: IMSI
Number of subjects: 350
Study 23293218 — intervention group
Group type: COMPARATOR
Intervention: ICSI
Number of subjects: 350
Study 21552177 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol-soaked unworn lenses
Number of subjects: 0
Study 21552177 — intervention group
Group type: EXPERIMENTAL
Intervention: Worn PureVision lenses
Number of subjects: 0
Study 21552177 — intervention group
Group type: EXPERIMENTAL
Intervention: Worn Acuvue Oasys lenses
Number of subjects: 0
Study 21552177 — intervention group
Group type: COMPARATOR
Intervention: Cholesterol
Number of subjects: 0
Study 18710745 — intervention group
Group type: EXPERIMENTAL
Intervention: 1996 trials
Number of subjects: 152
Study 18710745 — intervention group
Group type: EXPERIMENTAL
Intervention: 2004 trials
Number of subjects: 152
Study 15970791 — intervention group
Group type: EXPERIMENTAL
Intervention: Val/Val genotype
Number of subjects: 1271
Study 15970791 — intervention group
Group type: COMPARATOR
Intervention: Ile/Ile genotype
Number of subjects: 1271
Study 12488964 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured group treatment and teaching programmes for Type I diabetes
Number of subjects: 0
Study 12488964 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured group treatment and teaching programmes for non-insulin dependent Type II diabetes
Number of subjects: 0
Study 12488964 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured group treatment and teaching programmes for hypertension
Number of subjects: 0
Study 12488964 — intervention group
Group type: EXPERIMENTAL
Intervention: Phased approach defining sequential stages of a continuum of increasing evidence
Number of subjects: 0
Study 10512131 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 alone at 6 x 10(6) Cetus units/m2 3 days weekly
Number of subjects: 76
Study 10512131 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 plus beta-IFN at 5 x 10(6) Cetus units/m2 plus beta-IFN at 6 x 10(6) units/m2, both given 3 days weekly
Number of subjects: 76
Study 10512131 — intervention group
Group type: COMPARATOR
Intervention: IL-2 (both groups combined)
Number of subjects: 76